🇺🇸 FDA
Patent

US 11331346

Targeted replacement of endogenous T cell receptors

granted A61KA61K40/11A61K40/32

Quick answer

US patent 11331346 (Targeted replacement of endogenous T cell receptors) held by The Regents of the University of California expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K40/11, A61K40/32, A61K40/4269